Article

Pharmacogenomic predictors of drug response and choice in dyslipidemia and hypertension

2026-01-30

Abstract excerpt

<h4>Background</h4> Drug suitability is determined by safety, efficacy, and pathological appropriateness. The pharmacogenomics of drug suitability can be assessed by analyzing drug response and drug choice in large population cohorts. <h4>Methods</h4> We investigated drug response and drug choice for dyslipidemia and hypertension using genetic, phenotypic, and prescribing data from the UK Biobank and the All of...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: da6814e2-6745-5ba9-b82c-e0451d65bf91
DOI: 10.64898/2026.01.28.26345024

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomic predictors of drug response and choice in dyslipidemia and hypertensionDOI 10.64898/2026.01.28.26345024Read

Characterizing the genetic architecture of drug response using gene-context interaction methods.Semantic proximity Read

Leveraging large-scale biobank EHRs to enhance pharmacogenetics of cardiometabolic disease medicationsSemantic proximity Read

A factorial Mendelian randomization study to systematically prioritize genetic targets for the treatment of cardiovascular diseaseSemantic proximity Read

Hypertension precision medicine: the promise and pitfalls of pharmacogenomicsSemantic proximity Read

Metabolomic signatures of lipid-modifying therapies using drug target Mendelian randomizationSemantic proximity Read

Leveraging large-scale biobank EHRs to enhance pharmacogenetics of cardiometabolic disease medicationsSemantic proximity Read

Biobank scale pharmacogenomics informs the genetic underpinnings of simvastatin useSemantic proximity Read

Characterizing the genetic architecture of drug response using gene-context interaction methodsSemantic proximity Read

<i>LPA</i> and <i>APOE</i> are associated with statin selection in the UK BiobankSemantic proximity Read

A Machine Learning Approach to Predicting Heterogeneous Lipid Responses to Statins in Type 2 DiabetesSemantic proximity Read

Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisationSemantic proximity Read

Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin Use.Semantic proximity Read